Diabetes Mellitus
Conditions
Keywords
diabetes
Brief summary
Continuous monitoring of the skin tissue glucose concentration on two different study days using glucose sensors that work on the principle of impedance spectroscopy, with systematic alteration of the blood glucose concentration using the glucose clamp technique in healthy subjects and subjects with type 1 diabetes. Simultaneous determination of electrolyte concentrations in the blood by taking frequent blood samples.
Detailed description
A completely non-invasive continuous glucose monitoring device is considered as a major target of glucose sensor development. The aim of this study is to evaluate the performance of a non-invasive glucose sensor (wristwatch) under controlled conditions (glucose clamp) at hyperglycemia (study day 1) and at hypoglycemia (study day 2). Measurements of the non-invasive glucose monitoring device are compared to those obtained from a minimally invasive glucose monitoring device (GlucoDay, microdialysis principle). In addition, changes in blood electrolyte concentrations as well as their impact on the measurements of the non-invasive glucose sensor are evaluated.
Interventions
DEVICENon-invasive CGMS (continuous glucose monitoring system)
A non-invasive continuous glucose monitoring device measure was applied at the wrist and measure skin glucose as an indirect measure of blood glucose every 10 min.
PROCEDUREHyperglycemic and hypoglycemic glucose clamp
The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (300 mg/dL) for 1.5 h, and euglycemia (100 mg/dL) for another 1.5 h. A continuous somatostatin infusion was initiated after the 2 h run-in period to suppress endogenous insulin secretion. A glucose solution was infused to increase blood glucose towards the hyperglycemic target level. At the end of the hyperglycemic level the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level. On a second study day a hypoglycemic clamp took place, where blood glucose after the run-in period of 2 h was lowered by means of intravenous insulin administration over a period of appr. 30 min to a hypoglycemic level of 45 mg/dL, where it was kept constant for appr. 30 min, after which blood glucose was raised to euglycemia (100 mg/dL) again by means of an intravenous glucose infusion and was kept there for 1.5 hours. .
DEVICENon-invasive CGMS (GlucoDay)
The minimally-invasive glucose sensor GlucoDay, was used as a control measure
Sponsors
Pendragon Medical AG Switzerland
Profil Institut für Stoffwechselforschung GmbH
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy male and female volunteers: * Written informed consent * Aged between 18 and 40 years * Body mass index between 18 and 28 kg/m² * Haemoglobin \> 13 g% Male and female patients with type 1 diabetes: * Known type 1 diabetes, first manifestation 6 months to 15 years before the start of the study * HbA1c \<= 9% * Written informed consent * Aged between 18 and 40 years * Body mass index between 18 and 28 kg/m² * Haemoglobin \> 13 g%
Exclusion criteria
* Uncontrolled arterial hypertension (diastolic blood pressure \>100 mmHg and/or systolic blood pressure \> 180 mmHg) * For women, pregnancy or breast-feeding or, for sexually active women of child-bearing age, the use of contraceptive methods considered to be safe (oral contraceptives, IUD, implanted or injected contraceptives, diaphragms, or surgical sterilisation of the patient or her partner) * Deviations in the lab values (excluding HbA1c), as judged by the investigator to be clinically significant, in particular an increase in transaminases to a level that is two and a half times higher than the upper normal value and a creatinine value that is above the normal range * Severe acute diseases, as judged by the investigator * Severe chronic disease, as judged by the investigator * History of macrovascular illnesses such as pAVK, myocardial infarction * Known microvascular (diabetic) complications (other than diabetic background retinopathy) * Positive serology for hepatitis B, hepatitis C or HIV * Blood donation within 3 months prior to the start of the study and intention of donating blood within 3 months after the end of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| skin tissue glucose concentration | continuously during the glucose clamp |
Secondary
| Measure | Time frame |
|---|---|
| serum and urine electrolyte concentrations (sodium, potassium, chloride, calcium, magnesium, urea, osmolarity, pH, lactate, p(O2), standard bicarbonate, p(CO2), blood glucose concentration | at 5 min intervals between the individual plateau phases, at 10 min intervals during the plateau phases (of the blood glucose concentration) |
Countries
Germany
Outcome results
None listed